Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Alector Inc

Healthcare US ALEC

1.825USD
0.04(2.53%)

Last update at 2026-06-23T14:53:00Z

Day Range

1.721.87
LowHigh

52 Week Range

0.973.40
LowHigh

Fundamentals

  • Previous Close 1.78
  • Market Cap271.49M
  • Volume117114
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-147.36701M
  • Revenue TTM21.05M
  • Revenue Per Share TTM0.20
  • Gross Profit TTM -102.02000M
  • Diluted EPS TTM-1.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -142.76100M -118.92100M -125.17900M -130.05600M -36.32900M
Minority interest - - - - -
Net income -142.92900M -119.04900M -130.39100M -133.31000M -28.01400M
Selling general administrative 53.99M 59.62M 56.69M 61.03M 55.04M
Selling and marketing expenses - - - - -
Gross profit 11.38M 100.56M 88.21M 133.62M 207.09M
Reconciled depreciation 9.66M 8.84M 8.70M 8.47M 8.31M
Ebit -142.76100M -144.99700M -151.74000M -146.30600M -45.67500M
Ebitda -133.10000M -136.15600M -142.89200M -137.83400M -37.36000M
Depreciation and amortization 9.66M 8.84M 8.85M 8.47M 8.31M
Non operating income net other - - - - 1.03M
Operating income -145.80700M -144.99700M -151.74000M -137.83400M -37.36000M
Other operating expenses 166.85M 245.56M 248.80M 271.45M 244.44M
Interest expense - - - -16.25000M 8.31M
Tax provision 0.17M 0.13M 4.27M 3.25M -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.17M 0.13M 5.21M 3.25M -8.31500M
Total revenue 21.05M 100.56M 97.06M 133.62M 207.09M
Total operating expenses 157.19M 245.56M 239.95M 271.45M 244.44M
Cost of revenue 9.66M 8.84M 8.85M - -
Total other income expense net 3.05M 26.08M 26.56M 7.78M 1.03M
Discontinued operations - - - - -
Net income from continuing ops -142.92900M -119.04900M -141.38500M -133.31000M -36.32900M
Net income applicable to common shares - - - -133.31000M -36.32900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 293.24M 468.30M 621.83M 787.65M 814.66M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 10.43M 11.42M 16.95M 11.00M 7.07M
Total liab 262.59M 341.50M 487.67M 573.21M 513.93M
Total stockholder equity 30.65M 126.80M 134.16M 214.44M 300.72M
Deferred long term liab - - - - -
Other current liab 51.71M 90.43M 82.74M -14.90100M -55.12900M
Common stock 0.01M 0.00900M 0.00800M 0.00800M 0.00800M
Capital stock 0.01M 0.00900M 0.00800M 0.00800M 0.00800M
Retained earnings -972.05600M -829.12700M -710.07800M -579.68700M -446.37700M
Other liab - - - 444.13M 334.57M
Good will - - - - -
Other assets - - - 7.88M 7.05M
Cash 65.80M 33.02M 74.56M 154.32M 329.15M
Cash and equivalents - - - - -
Total current liabilities 69.50M 125.06M 177.95M 45.58M 48.22M
Current deferred revenue 6.68M 23.66M 82.97M 48.23M 90.80M
Net debt -29.56900M 9.50M -35.63700M -110.99600M -281.55100M
Short term debt 9.42M 8.75M 8.46M 8.06M 7.79M
Short long term debt 0.37M - - - -
Short long term debt total 36.23M 42.52M 38.92M 43.33M 47.60M
Other stockholder equity 1002.53M 955.66M 844.04M 798.70M 748.04M
Property plant equipment - - - 53.33M 27.33M
Total current assets 266.45M 424.82M 565.81M 726.43M 749.71M
Long term investments - - - - -
Net tangible assets - - - 214.44M 300.72M
Short term investments 190.22M 380.38M 474.31M 558.53M 406.10M
Net receivables - - - 2.59M 7.39M
Long term debt 9.32M 9.39M - - -
Inventory - - - - -
Accounts payable 1.69M 2.21M 3.77M 4.19M 4.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.17M 0.26M 0.18M -4.57500M -0.94300M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -446.37700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.23M 6.39M 7.42M 7.88M 7.05M
Deferred long term asset charges - - - - -
Non current assets total 26.79M 43.49M 56.02M 61.21M 64.94M
Capital lease obligations 26.54M 33.13M 38.92M 43.33M 47.60M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 196.64M 107.13M 102.23M -159.01400M -46.41600M
Change to liabilities - - - 65.81M 1.60M
Total cashflows from investing activities 196.60M 107.13M 101.92M -159.01400M -49.66300M
Net borrowings 0.00000M 9.39M 0.00000M - -
Total cash from financing activities 20.21M 81.54M 2.55M 4.51M 30.30M
Change to operating activities - - - -6.28500M -11.15100M
Net income -142.92900M -119.04900M -130.39100M -133.31000M -36.32900M
Change in cash 32.78M -41.23400M -79.69400M -174.82900M 279.18M
Begin period cash flow 34.87M 76.10M 155.79M 330.62M 51.44M
End period cash flow 67.65M 34.87M 76.10M 155.79M 330.62M
Total cash from operating activities -184.03100M -229.90500M -184.16200M -20.32900M 298.55M
Issuance of capital stock 19.98M 71.11M 0.00000M 0.00000M 0.00000M
Depreciation -0.86100M 8.84M 8.85M 8.47M 8.31M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - -2.58700M - -
Change to account receivables - - 2.59M - -
Sale purchase of stock - - - - 30.30M
Other cashflows from financing activities 0.22M 1.04M 2.55M 1.46M 30.30M
Change to netincome - - - 44.98M 40.78M
Capital expenditures 0.04M 1.25M 2.38M 4.12M 3.25M
Change receivables - - - - -
Cash flows other operating - - - - 284.06M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 279.18M
Change in working capital -74.05700M -146.98600M -90.14700M 59.53M 283.68M
Stock based compensation 26.66M 39.46M 42.80M 46.15M 40.78M
Other non cash items 7.16M -12.17400M -15.27000M -1.16300M 2.10M
Free cash flow -184.07200M -231.16000M -186.54300M -24.44600M 295.30M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALEC
Alector Inc		 0.04 2.53% 1.82 - 8.47 12.90 9.74 3.74 -8.3996
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector Inc

131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Tillman Ulf Gerngross Ph.D. Co-Founder & Chairman 1964
Dr. Arnon Rosenthal Ph.D. Co-Founder, CEO & Director 1956
Dr. Sara Kenkare-Mitra Ph.D. Pres and Head of R&D 1968
Mr. Calvin Yu VP of Fin. 1976
Dr. Marc Grasso M.D. Chief Financial Officer 1974
Mr. Peter Heutink Ph.D. Chief Scientific Officer NA
Michelle Corral VP of Communications & Investor Relations NA
Ms. Danielle Pasqualone J.D., Ph.D. Gen. Counsel NA
Erica Jefferson VP of Communications & Public Affairs NA
Ms. Clare Hunt M.B.A. Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.